Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,883 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
Copie-Bergman C, Gaulard P, Leroy K, Briere J, Baia M, Jais JP, Salles GA, Berger F, Haioun C, Tilly H, Emile JF, Banham AH, Mounier N, Gisselbrecht C, Feugier P, Coiffier B, Molina TJ. Copie-Bergman C, et al. Among authors: berger f. J Clin Oncol. 2009 Nov 20;27(33):5573-9. doi: 10.1200/JCO.2009.22.7058. Epub 2009 Sep 28. J Clin Oncol. 2009. PMID: 19786664 Clinical Trial.
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).
Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H, Bouabdallah R, Reyes F, Gaulard P, Coiffier B. Mounier N, et al. Among authors: berger f. Blood. 2003 Jun 1;101(11):4279-84. doi: 10.1182/blood-2002-11-3442. Epub 2003 Feb 6. Blood. 2003. PMID: 12576316 Free article. Clinical Trial.
Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study.
Dupuis J, Emile JF, Mounier N, Gisselbrecht C, Martin-Garcia N, Petrella T, Bouabdallah R, Berger F, Delmer A, Coiffier B, Reyes F, Gaulard P; Groupe d'Etude des Lymphomes de l'Adulte (GELA). Dupuis J, et al. Among authors: berger f. Blood. 2006 Dec 15;108(13):4163-9. doi: 10.1182/blood-2006-04-017632. Epub 2006 Aug 10. Blood. 2006. PMID: 16902151 Free article. Clinical Trial.
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ, Canioni D, Copie-Bergman C, Recher C, Brière J, Haioun C, Berger F, Fermé C, Copin MC, Casasnovas O, Thieblemont C, Petrella T, Leroy K, Salles G, Fabiani B, Morschauser F, Mounier N, Coiffier B, Jardin F, Gaulard P, Jais JP, Tilly H. Molina TJ, et al. Among authors: berger f. J Clin Oncol. 2014 Dec 10;32(35):3996-4003. doi: 10.1200/JCO.2013.54.9493. Epub 2014 Nov 10. J Clin Oncol. 2014. PMID: 25385729 Clinical Trial.
The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.
Jais JP, Haioun C, Molina TJ, Rickman DS, de Reynies A, Berger F, Gisselbrecht C, Brière J, Reyes F, Gaulard P, Feugier P, Labouyrie E, Tilly H, Bastard C, Coiffier B, Salles G, Leroy K; Groupe d'Etude des Lymphomes de l'Adulte. Jais JP, et al. Among authors: berger f. Leukemia. 2008 Oct;22(10):1917-24. doi: 10.1038/leu.2008.188. Epub 2008 Jul 10. Leukemia. 2008. PMID: 18615101 Free PMC article.
Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.
Fermé C, Mounier N, Diviné M, Brice P, Stamatoullas A, Reman O, Voillat L, Jaubert J, Lederlin P, Colin P, Berger F, Salles G. Fermé C, et al. Among authors: berger f. J Clin Oncol. 2002 Jan 15;20(2):467-75. doi: 10.1200/JCO.2002.20.2.467. J Clin Oncol. 2002. PMID: 11786576 Clinical Trial.
Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis.
Ghesquières H, Berger F, Felman P, Callet-Bauchu E, Bryon PA, Traverse-Glehen A, Thieblemont C, Baseggio L, Michallet AS, Coiffier B, Salles G. Ghesquières H, et al. Among authors: berger f. J Clin Oncol. 2006 Nov 20;24(33):5234-41. doi: 10.1200/JCO.2006.07.5671. Epub 2006 Oct 16. J Clin Oncol. 2006. PMID: 17043351
Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.
Bossard C, Belhadj K, Reyes F, Martin-Garcia N, Berger F, Kummer JA, Brière J, Baglin AC, Cheze S, Bosq J, Ribrag V, Gisselbrecht C, Mounier N, Gaulard P. Bossard C, et al. Among authors: berger f. Blood. 2007 Mar 1;109(5):2183-9. doi: 10.1182/blood-2006-07-033142. Epub 2006 Oct 31. Blood. 2007. PMID: 17077322 Free article. Clinical Trial.
1,883 results